NCT07197008View on ClinicalTrials.gov

Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions
Lung Cancer
Interventions
DRUG

Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab

Eligible patients will receive Sacituzumab tirumotecan at a dose of 4 mg/kg in combination with bevacizumab 5mg/kg by intravenous infusion on day 1 and day 15 of each 28-day cycle.

All Listed Sponsors
lead

Li-kun Chen

OTHER